Onsite buprenorphine inductions at harm reduction agencies to increase treatment engagement and reduce HIV risk: Design and rationale.

ABSTRACT:

Background

Despite dramatic increases in opioid use disorder (OUD) and overdose deaths, the U.S. has been unable to consistently deliver OUD treatment to those who need it. Syringe services programs (SSPs) can engage an out-of-treatment population of people with OUD that has elevated overdose risk. Buprenorphine treatment is safe and effective, and US regulations allow for prescribing from diverse locations, including SSPs. This study's objective is to test buprenorphine treatment initiation at SSPs. We hypothesize that offering onsite buprenorphine treatment initiation will improve OUD treatment engagement without reducing buprenorphine treatment effectiveness or safety.

Methods

We will recruit 250 out-of-treatment SSP participants with OUD in a large urban area. Participan

SUBMITTER: Perez-Correa A 

PROVIDER: S-EPMC10123766 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature